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Abstract
Background: The insulin-like growth factor (IGF) axis is an important signaling pathway in the
growth and survival of many cell and tissue types. This pathway has also been implicated in many
aspects of cancer progression from tumorigenesis to metastasis. The multiple roles of IGF signaling
in cancer suggest that inhibition of the pathway might yield clinically effective therapeutics.
Methods: We describe A-928605, a novel pyrazolo [3,4-d]pyrimidine small molecule inhibitor of
the receptor tyrosine kinases (IGF1R and IR) responsible for IGF signal transduction. This
compound was first tested for its activity and selectivity via conventional in vitro kinome profiling
and cellular IGF1R autophosphorylation. Additionally, cellular selectivity and efficacy of A-928605
were analyzed in an IGF1R oncogene-addicted cell line by proliferation, signaling and microarray
studies. Finally, in vivo efficacy of A-928605 was assessed in the oncogene-addicted cell line and in
a neuroblastoma model as a single agent as well as in combination with clinically approved
therapeutics targeting EGFR in models of pancreatic and non-small cell lung cancers.
Results: A-928605 is a selective IGF1R inhibitor that is able to abrogate activation of the pathway
both in vitro and in vivo. This novel compound dosed as a single agent is able to produce significant
growth inhibition of neuroblastoma xenografts in vivo. A-928605 is also able to provide additive
effects when used in combination with clinically approved agents directed against EGFR in non-small
cell lung and human pancreatic tumor models.
Conclusion: These results suggest that a selective IGF1R inhibitor such as A-928605 may provide
a useful clinical therapeutic for IGF pathway affected tumors and warrants further investigation.
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Insulin-like growth factor signaling plays an important
role in development and adult homeostasis by supporting
growth and survival of multiple cell and tissue types [1].
These important functions are a direct result of the ability
of IGF signaling to activate both the anti-apoptotic AKT
pathway and the mitogenic extracellular signal regulated
kinase (ERK) pathway [1]. However, when this elegantly
balanced multi-component signaling system is perturbed,
the dual roles of IGF signaling in both survival and prolif-
eration make this pathway a likely contributor to cancer
biology. Aberrant IGF signaling has been implicated in
multiple aspects of tumor progression including onco-
genic transformation, cell proliferation, evasion of apop-
tosis, tumor cell invasion and metastases [1,2].
Additionally, IGF signaling has been implicated in resist-
ance to multiple current clinical therapeutics [3-8]. These
central roles in tumor initiation, growth and progression
make the IGF pathway an ideal candidate pathway to tar-
get therapeutically.
IGF pathway signal transduction is thought to occur exclu-
sively through extracellular ligand activation of the insu-
lin-like growth factor-1 receptor (IGF1R) and the insulin
receptor (IR) [9]. These plasma membrane proteins are
members of the receptor tyrosine kinase family and are
composed of two extracellular α-subunits disulfide
bonded to two single pass membrane spanning β-subu-
nits that contain the cytoplasmic tyrosine kinase activity.
The receptors are present either as homodimers or hybrid
receptors composed of IGF1R and IR heterodimers, and
are activated by binding of the ligands IGF1 and IGF2, as
well as insulin when the hybrid receptor is present [10].
The insulin receptor has two alternatively spliced variants
known as IRA and IRB. IRA is missing exon 11 which
encodes an extra 12 amino acids for the alpha subunit of
the IRB form of the receptor. IRB binds to only insulin
while IRA is known to associate with both insulin and
IGF2 [11]. IGF1 acts both as a circulating hormone and as
a tissue growth factor and is expressed in most normal tis-
sues, while IGF2 is predominantly a pre-natal growth hor-
mone in humans [1,12]. Binding of these ligands to the
receptors initiates various signaling cascades that ulti-
mately lead to the anti-apoptotic and proliferative signals
through the AKT and ERK pathways, respectively. After lig-
and binding the receptors become autophosphorylated
and activate downstream signaling pathways that ulti-
mately lead to proliferation through effects on cell cycle
proteins like Cyclin D1 and p27 [13]. In addition, survival
is increased, for instance, by phosphorylation of the pro-
apoptotic protein Bad by AKT and ERK, which results in
its sequestration and inactivation by 14-3-3 [14].
The ligand-dependent activation of IGF signal transduc-
tion and numerous pathway players increases the com-
plexity of the role of this pathway in cancer. Multiple
studies indicate the presence of increased circulating levels
of IGF1 in the plasma of patients with prostate, breast and
colon cancers [15]. Several studies also implicate over-
expression of IGF2 in colon cancer and in ovarian cancer
[15]. This increase in IGF2 expression in colon and ovar-
ian cancer is likely the result of a loss of imprinting as
both the maternal and paternal forms of this gene are seen
in a significant number of these patients [16,17]. In addi-
tion, several studies also suggest that there are a number
of tumors that show a higher expression level of IGF1R as
well as an increased ratio of IRA to IRB [15,18,19].
In this study, we report on the in vitro and in vivo activity
of a novel pyrazolo [3,4-d]pyrimidine small molecule
inhibitor of IGF1R, A-928605. This compound was found
to be selective when analyzed in a panel of in vitro kinase
assays, followed by profiling in vivo with a novel IGF1R
driven tumor model. Since there are no known activating
mutations for IGF1R, we generated a constitutively acti-
vated chimeric receptor that is capable of transforming
NIH-3T3 cells into a rapidly growing xenograft flank
tumor model that is shown to be exquisitely dependent
upon IGF signal transduction. The effects of A-928605 in
this transformed cell line were directly compared to its
effects in the non-transformed control cell line, and result-
ing data demonstrated that its biological activities are pre-
dominantly mechanism-based. The overall positive effects
led to analysis of this compound in a patient derived cell
line models of neuroblastoma as well as combination
studies in non-small cell lung cancer (NSCLC) and pan-
creatic carcinoma in which the small molecule inhibitor
A-928605 was shown to be efficacious.
Methods
Small-molecule inhibitors
Lapatinib, gefitinib, dastinib, sorafinib, imatinib and erlo-
tinib were prepared using published synthetic procedures.
A-928605 was prepared as previously described [20].
Molecular biology and cell lines
NIH-3T3, SK-N-FI, MiaPaCa-2 and HCC827 cell lines
were obtained from the American Type Culture Collection
(ATCC, Manassas, VA). Cell lines were cultured and
expanded in media according to ATCC guidelines. CD8-
IGF1R was generated by an in-frame fusion of the extracel-
lular and transmembrane domains of the human CD8α
coding sequence (amino acids 1-207) followed by a
BamHI restriction site to the cytoplasmic domain of
human IGF1R (amino acids 959-1368). This product was
cloned into the pIRESpuro3 vector (Clontech, Mountain
View, CA) via AflII/NotI adaptors. NIH-3T3 CD8-IGF1R
and vector control lines were generated by transfection of
these constructs with FuGENE 6 (Roche Diagnostics,
Basel, Switzerland) followed by selection with 2 μg/mlPage 2 of 14
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onies were screened for expression of the transgene. Cell
clones positive for CD8-IGF1R expression and vector
alone transfectants were pooled and remained under
puromycin selection for the duration of the study.
Proliferation and soft agar assays
Cells grown in soft agar were plated at 5,000 cells/well in
12-well tissue culture plates in a top layer of 0.3% noble
agar on a 0.7% bottom layer. Media containing the final
desired concentration of small molecule inhibitor was
used as the agar overlay. For proliferation assays, 5,000
cells per well were plated in 96-well tissue culture treated
plates and allowed to attach overnight. The following day
small molecule inhibitors or DMSO control were added
in duplicate at the indicated concentrations and cells were
placed in tissue culture incubators for 72 hours. Cell via-
bility was determined by an MTS assay (CellTiter Aqueous
One, Promega, Madison, WI).
Western blot analyses
Antibodies used included rabbit anti-ERK1/2 pTpY185/
187 (Biosource, Camarillo, CA), rabbit anti-IGF-1Rβ and
rabbit anti-Cyclin D1 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), rabbit anti-phospho-IGF-1Rβ (Tyr1135/
1136)/IR (Tyr1150/1151), rabbit antiphospho-AKT
(S473), rabbit anti-AKT, rabbit anti-ERK1/2, (Cell Signal-
ing Technology, Inc., Beverly, MA) and mouse anti-ACTIN
(Sigma, St. Louis, MO). All cell lysate samples were lysed
directly in 2× LDS NuPAGE sample buffer with reducing
reagent (Invitrogen, Carlsbad, CA) and were analyzed for
levels of phosphorylated and total signaling proteins by
Western blotting using the NuPAGE electrophoresis and
transfer systems (Invitrogen, Carlsbad, CA) and near
infrared detection.
DNA microarray analysis
Cells were treated with 1 μM of compound or DMSO con-
trol (0.000002% final concentration) and grown under
normal conditions for 24 hours. Cells were then directly
lysed in QIAzol RNA lysis reagent (Qiagen, Valencia, CA).
Samples were homogenized using an Ultra Turrax T 25
homogenizer (IKA, Wilmington, SC) and then processed
with the RNeasy 96 Universal Tissue 8000 kit (Qiagen,
Valencia, CA) using a BioRobot 3000 liquid handler (Qia-
gen, Valencia, CA) and a Sigma 4K15C centrifuge (Sigma,
Osterode am Harz, Germany) according to the Qiagen-
prescribed protocol. Approximately 2 μg of total RNA for
each sample were converted into 20 μg of fragmented,
biotin-labeled cRNA with a TargetPrep BioRobot 3000
(Qiagen, Valencia, CA) using a SuperScript Double-
Stranded cDNA Synthesis Kit (Invitrogen, Carlsbad, CA),
T7-Oligo(dT) primer (Integrated DNA Technologies, Cor-
alville, IA), MessageAmpTM II-Biotin Enhanced In Vitro
Transcription Reagents (Ambion, Austin, TX), and 5×
Fragmentation Buffer (Qiagen, Valencia, CA). Ten micro-
grams of fragmented, labeled cRNAs for each sample were
hybridized with an Affymetrix Mouse Genome 430A 2.0
array (Affymetrix, Santa Clara, CA) using standard
Affymetrix protocols. After hybridization, the chips were
washed and stained using Affymetrix GeneChip
Fluidics_450 Stations and visualized with the Affymetrix
GeneChip Scanner. GeneChip Operating Software
(v1.4.036) was used to quantify perfect match and mis-
match features on the scanned microarray images. After
quantification, quality control was assured using the
Affymetrix Power Tools Quality Reporter (v1.0.04) qual-
ity control metrics.
Data normalization and analysis were performed using
Resolver 7.0 software (Rosetta Inpharmatics, Seattle, WA).
Ratios were built for the average of each treatment versus
the group average and a p-value was calculated for every-
fold change using the Resolver Affymetrix error model
[21]. Transcripts and experimental treatments were
grouped for visualization by agglomerative hierarchical
clustering using the Pearson correlation and the average
link in as described in each figure. Probes with a difference
of +/- 1.5-fold with a False Discovery Rate (FDR) < 0.05
were considered statistically significant [22]. Transcripts
that had statistically significant differences vs. the vehicle
control group were investigated through the use of Inge-
nuity Pathway Analysis (IPA) version 6.5 software (Inge-
nuity Systems, Redwood City, CA) to identify the most
significantly over-represented biological pathways and
categories of gene ontology with coordinated gene regula-
tion. Array data has been deposited in the public Gene
Expression Omnibus database, accession GSE14024.
Tumor implantation and anti-tumor efficacy studies
All animal studies were conducted in accordance with the
guidelines established by the internal Institutional Ani-
mal Care and Use Committees. For CD8 IGF1R flank
tumors, 5.0 × 105 cells/mouse were mixed with an equal
volume of Matrigel (BD Biosciences) and injected subcu-
taneously into the flank of 6- to 8-week-old female nu/nu
mice (22 g; Charles River Laboratories). The tumors were
allowed to grow approximately 225 mm3, and mice were
reassigned into treatment groups (N = 10) based on tumor
volume. At the initiation of treatment, the mean tumor
volume ± SEM of the groups was approximately 231 ± 10
mm3. For MiaPaCa-2 flank tumors, 1.0 × 106 cells/mouse
were mixed with an equal volume of Matrigel and injected
subcutaneously into the flank of 6- to 8-week-old female
SCID mice (20 g; Charles River Laboratories). The tumors
were allowed to grow approximately 225 mm3, and mice
were reassigned into treatment groups (N = 10) based on
tumor volume. At the initiation of treatment, the mean
tumor volume ± SEM of the groups was approximately
210 ± 30 mm3. For HCC-827 flank tumors, a brei wasPage 3 of 14
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in mice and injected subcutaneously into the flank of 6- to
8-week-old female SCID mice (20 g; Charles River Labo-
ratories). The tumors were allowed to grow approximately
225 mm3, and mice were reassigned into treatment
groups (N = 10) based on tumor volume. At the initiation
of treatment, the mean tumor volume ± SEM of the
groups was approximately 300 ± 20 mm3. In all flank
models, tumor growth was periodically analyzed by meas-
urement with digital calipers and tumor volume was esti-
mated from the formula (L × W 2)/2. For all flank models,
the effect of treatment on tumor growth rate was assessed
by determining %T/C [(mean tumor volume of treated
group on day X ÷ mean tumor volume of control group on
day X) × 100].
For SK-N-FI renal subcapsule tumors, mice were anesthe-
tized with intramuscular injections of ketamine (40 mg/
kg) and rompum (5 mg/kg) before surgery. A small inci-
sion was made along the right flank of the mouse and
0.01 ml of 2 × 106 SK-N-FI cells were mixed with an equal
volume of Matrigel and injected just under the subcapsule
of the exposed kidney of 10-12 week old male SCID mice
(25 g; Charles River Labs). The peritoneal cavity was
closed with 4-0 suture and skin incision was closed with
clip. Fourteen days after tumor cell injection, tumor
growth was assessed in cohort mice by necropsy (see Fig-
ure 1B) and study mice were reassigned at that time to
treatment groups (N = 10) based on injection order. At the
end of the dosing period, tumor weight was determined
by comparing the weight of the tumor bearing kidney to
that of the contralateral kidney. The effect of treatment on
tumor growth was assessed by determining %T/C [(mean
tumor weight of treated group on day X ÷ mean tumor
weight of control group on day X) × 100].
For all animal studies, administration of therapeutic com-
pounds are described in the figure legends.
Statistical analysis
Differences between specified groups were analyzed using
the Student's t test (two-tailed) for comparing two groups,
with P < 0.05 considered statistically significant.
Efficacy of A-928605 in the SK-N-FI neuroblastoma xenograft as a renal subcapsule modelFigure 1
Chemical structure and activity of A-928605. A, The chemical name of A-928605 is 3-(2-(2-chlorobenzyl)-1 H-benzo 
[d]imidazol-5-yl)-1-((1 r, 4 r)-4-morpholinocyclohexyl)-1 H-pyrazolo [3,4-d]pyrimidin-4-amine. B, Kinome profile analysis of A-
928605 on 156 unique kinases. Heat map colors correspond to the relative Ki against each kinase, where Ki greater than 1,000 
nM are colored green, near 100 nM are yellow and Ki of roughly 10 nM are shaded red.Page 4 of 14
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A-928605 is a potent and selective kinase inhibitor of 
IGF1R
We originally recognized that the pyrazolopyrimidine
class of kinase inhibitors possessed moderate potency for
IGF1R during a high throughput screen of our compound
repository [20]. A-928605 (Figure 2A) is an optimized
pyrazolopyrimidine that has previously been reported to
have an IGF1R in vitro enzymatic IC50 of 37 nM as well as
an IC50 value of 90 nM for inhibition of cellular IGF1R
phosphorylation induced by IGF1 in A431 tumor cells
[20]. This small molecule inhibitor was tested against an
in vitro panel of 156 kinases for potential enzyme inhibi-
tion and was found to have a Ki of less than 10 nM in only
5 of those kinases (Figure 2B). Two of these five kinases,
IGF1R and the closely related IR, were desired targets and
confirmed by cellular analysis. However, the three other
kinase activities with Ki values below 10 nM could not be
confirmed in cellular assays. For example, A-928605 has
an IC50 value for inhibition of A-431 and HCC827 cellular
epidermal growth factor receptor (EGFR) phosphoryla-
tion of > 10 μM.
A-928605 reverses IGF1R-dependent transformation
The multiple members of the IGF axis, the lack of known
receptor activating mutations and the ligand-dependent
nature of IGF signal transduction make this pathway diffi-
cult to model both in vitro and in vivo. To bypass these
inherent complications, we utilized a previously pub-
lished technique where fusion of the extracellular
sequence of the human T-cell antigen CD8α to the cyto-
plasmic domain of receptor tyrosine kinases leads to con-
stitutively active receptor kinases that can act as oncogenes
[23-25]. CD8α extracellular peptides are known to form
dimers [26], and when fused to the cytoplasmic tail of a
receptor tyrosine kinase this dimerization results in the
kinase domains being brought into proximity and allows
constitutive activation. NIH-3T3 cells with over-expressed
CD8-IGF1R were generated and the resulting cell line has
a strongly constitutively phosphorylated IGF1R cytotail
(Figure 3A). After transfection and selection, the surviving
CD8-IGF1R positive cells had morphology suggestive of
oncogenic transformation by the chimeric protein (see
Additional File 1: Supplemental Figure S1A). Treatment of
the CD8-IGF1R cell line with increasing amounts of A-
Figure 2
A-928605 is a potent inhibitor of IGF signal transduction as seen in a model tra sformed cell lineFigure 2
A-928605 is a potent inhibitor of IGF signal transduc-
tion as seen in a model transformed cell line.A, Paren-
tal NIH 3T3 cells compared to the vector control and CD8-
IGF1R lines show a strong pIGF1R signal in the CD8-IGF1R 
line. All cells were grown in normal growth media containing 
10% FBS. B, Cells were treated for 1 hour with A-928605 in 
a dose response analysis as shown. The CD8-IGF1R fusion 
protein runs as a doublet [25]. C and D, Three day prolifer-
ation assay in the NIH-3T3 vector control cells (C) or CD8-
IGF1R cells (D) with increasing amounts of six clinical small 
molecule inhibitors and A-928605. Compounds were run in 
duplicate at each indicated concentration. Results are repre-
sentative of 5 separate assays. Intended targets of each small 
molecule inhibitor are as follows: lapatinib, ERBB2 and EGFR; 
gefitinib, EGFR; dasatinib, ABL and SRC; Sorafinib, multi-tar-
geted; imatinib, ABL and KIT; erlotinib, EGFR.  Page 5 of 14
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phosphorylation near its known cellular phosphorylation
IC50 value of ~100 nM (Figure 3B). So while the CD8-
IGF1R chimeric kinase is constitutively activated, this acti-
vation can be effectively reversed by intervention of the
ATP-competitive inhibitor A-928605. This can also be
seen at the morphological level as increasing concentra-
tions of A-928605 in the CD8-IGF1R cells results in a
reversal of their transformed phenotype (see Additional
File 1: Supplemental Figure S1B). A-928605 and six cur-
rent clinical therapeutic kinase inhibitors were subse-
quently tested for their ability to inhibit cellular
proliferation in the NIH-3T3 CD8-IG1R and vector con-
trol cell lines. While there is little effect of A-928605 in the
vector control cell line at concentrations sufficient for the
inhibition of cellular IGF1R (Figure 3C), it is a potent
inhibitor of cellular proliferation of the CD8-IGF1R cells
with an IC50 of less than 0.3 μM (Figure 3D), indicating
that these transformed cells now rely on IGF1R signaling
to proliferate. It is interesting to note the switch in signal-
ing dependence between the vector control and CD8-
IGF1R lines. Dasatinib (ABL and SRC inhibitor) is a
potent inhibitor of the vector control NIH-3T3 cells, but
has no effect on the CD8-IGF1R line at concentrations up
to 10 μM and none of the other known kinase inhibitors
tested showed anti-proliferative activities towards the
transformed cells at concentrations below 10 μM. A-
928605 is also capable of completely inhibiting the
anchorage-independent growth of the transformed NIH-
3T3 CD8-IGF1R line when grown in soft agar (see Addi-
tional File 2: Supplemental Figure S2). In total, these data
suggest that A-928605 can effectively inhibit cellular
IGF1R kinase activity and reverse the effects of IGF1R-
dependent transformation.
Expression signature of IGF1R transformation is selectively 
abrogated by A-928605
Microarray analysis was performed to assess the possible
molecular mechanisms underlying the IGF pathway-
Figure 3
A-928605 is a potent inhibitor of IGF signal transduction as seen in a model tra sformed cell lineFigure 3
A composite transcription signature is induced by 
CD8-IGF1R over-expression and A-928605 treat-
ment of the transformed cellsA, Expression profile of 
1860 Affymetrix probe sets that were differentially 
expressed between CD8-IGF1R and vector control cells and 
between CD8-IGF1R vehicle and A-928605-treated cells by 
at least 1.5-fold and with a 5% FDR. Three independent 
plates, each represented by a column on the heat map, were 
analyzed from the vehicle-treated vector control, A-928605-
treated vector control, vehicle-treated CD8-IGF1R, A-
928605-treated CD8-IGF1R cell groups. Genes exhibiting 
decreased expression in CD8-IGF1R relative to vector con-
trol cells represent classes I (579 transcripts) and II (162 
transcripts). Class III (968) and IV (151) transcripts exhibited 
increased expression in CD8-IGF1R relative to vector con-
trol cells. B, Relative expression level of key class I and III 
genes for each treatment group relative to vehicle-treated 
vector control cells. All vehicle treated vector control cells 
have gene expression normalized to 1.Page 6 of 14
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inhibition by A-928605 in the NIH-3T3 cell lines. Cells
were treated with 1 μM of compound or DMSO control
and grown under normal conditions for 24 hours. RNA
was isolated, and the microarray profiles were analyzed
for differential gene expression at a 5% False Discovery
Rate (FDR) [22]. A comparison of the vehicle-treated
CD8-IGF1R line with the vehicle-treated NIH-3T3 vector
control line revealed large gene expression changes
including 5,968 transcripts that showed significant
changes (5% FDR, fold change > 1.5) split evenly between
up- and down-regulation, of which approximately 2,931
were up regulated and 3,037 were down-regulated (Figure
4A). Ingenuity pathway analysis (IPA) of these genes indi-
cated that the constitutive IGF signaling leads to an up-
regulation in both mitogenic and anti-apoptotic pathways
at the transcriptional level. There is also a significant
quantitative increase in connective tissue and extracellu-
lar-matrix messenger RNAs including Tgfβ1 (2.4-fold) and
Vegfa (4.3-fold), aiding in the ability of the cells to grow
anchorage independently and as tumors (vide infra). As a
result of the constitutive activation of the IGF axis, the
mRNAs for the ligand Igf2, the native receptor Igf1r, and
IGF binding proteins Igfbp5 and Igfbp7 were down-regu-
lated, while Insig2, Igfbp4 and Igfbp6 were up-regulated,
suggesting an attempt at a compensatory down-regulation
of the IGF axis by the cell (see Additional File 3: Supple-
mental Table 1). Several transcriptional changes in the
insulin/IGF pathway observed in these CD8-IGF1R posi-
tive cells, such as decreases in the insulin receptor sub-
strate proteins, Irs1 and Irs2, have been reported for cells
treated with IGF1 [27].
The dramatic transcriptional changes induced by the con-
stitutive activation of IGF signaling in the CD8-IGF1R line
were largely reversed by treatment with A-928605 (Figure
4A). Of the 4,585 transcripts significantly changed in the
A-928605-treated CD8-IGF1R cells relative to vehicle-
treated CD8-IGF1R cells, 61% were down-regulated and
1860 transcripts overall were in common with those
5,968 transcripts regulated by CD8-IGF1R expression
(Figure 4A). By hierarchical clustering, these genes sepa-
rated into four major clusters. Classes I and II genes exhib-
ited decreased expression in CD8-IGF1R cells relative to
NIH-3T3 vector control cells. Class III and IV genes exhib-
ited increased expression in CD8-IGF1R relative to vector
control cells. Expression in class I and III genes were nor-
malized by A-928605 treatment. The transcripts in class III
Figure 4
A composite transcription signature is induced by CD8-IGF1R over-expression a d A-928605 treatment of the transformed cellsFigure 4
A-928605 abrogates modifications of IGF pathway 
signaling proteins in vitro and is efficacious in the 
CD8-IGF1R xenograft flank model in vivo. A, One 
hour of 1 mM A-928605 treatment in vector control and 
CD8-IGF1R cells results in inhibition of phosphorylation of 
the IGF1R cytotail and the immediate downstream pathway 
effectors AKT and ERK1/2. Cyclin D1 is a transcriptional tar-
get of the IGF signaling pathway and is therefore not affected 
by this one hour treatment. B, 24-hours of 1 mM A-928605 
treatment in vector control and CD8-IGF1R cells results in a 
significant decrease in Cyclin D1 expression as seen here and 
in the microarray results (Figure 3). C, Beginning on day 17 
post tumor cell injection, mice were dosed intraperitoneally 
with A-928605 at 50 mg/kg, twice daily (b.i.d)., or its vehicle 
for 10 days. At the end of the dosing schedule, the %T/C (A-
928605 vs. vehicle) was 21 (P < 0.00001).Page 7 of 14
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and proliferation, which was consistent with the status of
IGF signaling as potently mitogenic. Data analysis using
IPA software revealed regulation of the G1/S and G2/M
canonical pathways in both the CD8-IGF1R resting and
treated cells. Indeed, mRNA levels of numerous Cyclins
such as Ccne1, cell-division cycle proteins including
Cdc25c, and other genes related to cell proliferation like
Plk1, were up-regulated by CD8-IGF1R expression and
down-regulated upon treatment of the CD8-IGF1R posi-
tive cells by A-928605 (Figure 4B). Many of these genes
have previously been shown to be up-regulated by IGF1
treatment of MCF-7 cells or down-regulated by IGF1R-
antibody treatment of SK-N-AS xenograft tumors [27-29].
Other key genes regulated in those studies, such as Aurka,
Birc5, Dusp4, and Dusp6 were similarly regulated here
(Supplementary Table 1 and Figure 4B). Numerous other
growth factor signaling pathways besides the IGF axis
were also affected. For example, a variety of cytokines, epi-
dermal growth factors, neurotrophic growth factors, and
growth factor receptors were significantly up-regulated by
CD8-IGF1R expression and down-regulated upon A-
928605 treatment (Supplementary Table 1). In contrast,
several important growth factors, including Igf2 and Ogn,
the chemokines Cxcl5 and 12, and other growth factor
receptors had the opposite expression profile and were in
class I. The genes in class IV were up-regulated in CD8-
IGF1R cells relative to vector control cells and further up-
regulated by A-928605 treatment. Intriguingly, little over-
all effect on transcription was seen in the vector control
line when treated for 24 hours with A-928605, with no
statistically significant changes greater than 6-fold and
only ten transcripts significantly regulated at all. (Figure
4A, Supplementary Table 1). This almost negligible effect
on gene expression in the vector control line combined
with the in vitro kinase panel and the weak anti-prolifera-
tive effect shown in the vector control line in Figure 3C
further demonstrate the biological specificity of A-928605
in blocking the IGF axis.
Translational effects of A-928605 treatment on 
transformed versus control cells
The constitutively activated IGF signaling in the CD8-
IGF1R line results in phosphorylation of various signaling
proteins, including AKT and ERK1/2, that lead to changes
in proliferation via cell cycle control by up-regulation and
stabilization of proteins like Cyclin D1 (Figure 5A). As
expected, treatment of CD8-IGF1R cells with A-928605
leads to inhibition of the phosphorylation of the IGF1R
cytotail and downstream effectors AKT and ERK1/2
shortly after treatment (Figure 5A). The microarray analy-
ses shown in Figure 4 were performed on samples after 24
hours of A-928695 treatment to assess the transcriptional
changes that occur as a direct result of this pathway inhi-
bition seen in Figure 5A. The results of this analysis point
towards gene changes that lead to the significant inhibi-
tion of proliferation in the CD8-IGF1R cells versus the
vector control cells. One example is the 4.8-fold decrease
in Ccn d1 transcripts that occurs after 24 hours of A-
928605 treatment that is also visible at the translational
level (Figure 5B). The data collected at both the transcrip-
tional and translational levels in CD8-IGF1R transformed
cells treated with A-928605 provide evidence that this
small molecule is effective at inhibiting both the immedi-
ate modifications to the IGF signaling pathway as well as
its functional read-out in a highly specific manner.
A-928605 inhibits the growth of IGF1R driven tumors in 
vivo
CD8-IGF1R transformed 3T3 cells readily form xenograft
tumors when injected into the flanks of immunocompro-
mised mice (Figure 5C), while the NIH-3T3 vector control
cells are not capable of forming growing tumors when
injected into host animals (data not shown). We next
assessed the in vivo anti-tumor efficacy of A-928605 in
these CD8-IGF1R tumors. CD8-IGF1R tumors were grown
to 225 mm3 and then treated with the compound or vehi-
cle control for 10 days. A-928605 therapy was highly
effective at inhibiting growth of this tumor model and
resulted in an overall treated versus control (T/C) of 21%
at the end of dosing on day 26 of the study (Figure 5C). It
is interesting to note the efficiency of this model as tumors
can be size-matched at 225 mm3 in roughly 2 weeks post-
injection and compound efficacy can be determined in as
little as three to four days after initiation of dosing.
A-928605 is effective as a single agent therapy in a human 
neuroblastoma renal subcapsule model and in 
combination with other agents in pancreatic and NSCLC 
models
Tumor growth inhibition studies were also done utilizing
the human neuroblastoma cell line SK-N-FI, the human
pancreatic carcinoma line MiaPaCa-2 and the human
NSCLC line HCC827 to assess the activity of A-928605 in
non-engineered models. The SK-N-FI tumor analysis was
performed as autocrine IGF signaling has been associated
with the proliferation of neuroblastoma as well as other
childhood tumors [30,31]. Accordingly, A-928605 was
found to effectively inhibit proliferation of the SK-N-FI
cell line in vitro (Figure 1A). The in vivo experiment was
performed by surgical renal subcapsule injection of SK-N-
FI cells onto the right kidney capsule of experimental ani-
mals (Figure 1B). To assess the anti-tumor efficacy of A-
928605, mice were randomized on day 14 post SK-N-FI
cell injection, when tumor weights were approximately
0.07 g, as determined from cohort mice culled from the
study at that time. Treatment for 14 days with A-928605
(b.i.d., i.p.) resulted in a %T/C of 58 (p < 0.001) (Figure
1C &1D).Page 8 of 14
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the SK-N-FI model as a single agent led to the analysis of
this agent in other human tumor models in combination
with clinically approved therapeutics targeting EGFR. The
in vivo activity of A-928605 was first assessed in combina-
tion with cetuximab, a clinically approved EGFR mono-
clonal antibody, in the human pancreatic line MiaPaCa-2.
First, treatment mice bearing MiaPaCa-2 tumors with A-
928605 and cetuximab, alone and in combination,
resulted in significant monotherapy activity for each com-
pound, with %T/Cs of approximately 80 (P < 0.05) com-
pared to appropriate controls (Figure 6A). For
combination therapy with A-928605 and cetuximab, an
additive effect was seen, with the %T/Cs of approximately
72 (P < 0.05) when comparing the combination to each
monotherapy and %T/Cs of approximately 60 (P <
0.00001) when comparing the combination to the appro-
priate negative controls (Figure 6A). The in vivo activity of
A-928605 was also assessed in combination with erlo-
tinib, a clinically approved small molecule tyrosine kinase
inhibitor of EGFR, in the human NSCLC line HCC827.
The HCC827 cell line has greatly increased copy number
of the EGFR gene (> 20) and harbors an activating muta-
tion caused by a deletion within exon 19 of the EGFR cod-
ing sequence [32]. Treatment of size-matched HCC827
xenografts with A-928605 (data not shown) or erlotinib
results in partial responses within these study groups, but
the combination of these two therapies leads to a synergis-
tic response and regression of the tumors (Figure 6B).
These in vivo results suggest that A-928605 can be an effec-
tive therapeutic as a single agent in IGF-dependent
tumors, and it can also be quite effective in combination
therapy in tumors known to be sensitive to other targeting
agents.
Discussion
The approach of inhibiting IGF1R with a small molecule
is validated by the numerous receptor tyrosine kinases
(RTKs) that have been effectively targeted in the treatment
of cancer, including Bcr-Abl (imatinib), EGFR (erlotinib,
gefitinib) and EGFR/ErbB2 (lapatinib). The success of
these small molecule inhibitors in the clinic suggests that
numerous other RTKs can be exploited for both their roles
in oncogenesis and their relative druggability. The IGF sig-
naling pathway is a multi-component system that plays
important roles in both mitogenesis and apoptosis that
can ultimately lead to tumorigenesis. The main transduc-
ers of the IGF pathway are the RTKs IGF1R and IR. One
necessary consideration for targeting the IGF pathway are
potential effects on glucose homeostasis in generation of
an ATP-competitive inhibitor to IGF1R because of the
homology that exists between IGF1R and IR kinase
domains (84% similar) and their identical ATP binding
sites [33,34]. Indeed, we find that all IGF1R inhibitors
that we have generated, including A-928605, have
roughly equipotent IC50s against IGF1R and IR for both in
vitro enzyme activity and cellular phosphorylation data
(data not shown). This activity is potentially related to
increases in resting glucose levels in animal models and
patients that is seen after dosing of an IGF1R therapeutic
[35]. Despite these complications, the promising efficacy
thus far of these treatments in the clinic and the impor-
tance of the IGF pathway to human cancer biology war-
rant additional therapies to go forward into cancer
patients where aberrant IGF signaling may be implicated.
In this study we have shown the in vitro and in vivo anti-
proliferative effects of a novel pyrazolo [3,4-d]pyrimidine
IGF1R small molecule inhibitor. We have characterized A-
928605 in an in vitro kinase panel and an oncogene-
dependent model cell line that enables rapid analysis of
A-928605 abrogates modifications of IGF pathway signaling proteins in vitr  nd is effica ious in the CD8-IGF1R xenograft flank model in vivoFigure 5
Efficacy of A-928605 in the SK-N-FI neuroblastoma 
xenograft as a renal subcapsule model. A, A-928605 
inhibits proliferation of SK-N-FI cells in vitro. B-D, Beginning 
on day 14 post tumor cell injection, mice were dosed intra-
peritoneally with A-928605 at 37.5 mg/kg, b.i.d. for 14 days. 
B, Representative photograph taken of the tumor bearing 
and contralateral kidneys prior to the initiation of dosing on 
day 14 post tumor cell injection, indicating a tumor weight of 
0.07 g. C, Representative photograph taken of the tumor 
bearing and contralateral kidneys at the end of the dosing 
schedule (day 28). D, At the end of the dosing schedule, the 
%T/C (A-928605 vs. vehicle) was 58 (P < 0.001).Page 9 of 14
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vitro and in vivo. Using the CD8-IGF1R cell line as a screen-
ing tool, A-928605 was shown to be a potent inhibitor of
IGF-dependent proliferation. Because of the rapid growth
rate and oncogene dependence of the CD8-IGF1R tumor
model, the pharmacodynamic and pharmacokinetic
properties of A-928605 were ascertained in a tumor set-
ting in less than a week of compound dosing. Addition-
ally, the existence of the isogenic parental vector control
cell line served a function in assessing the general non-
specific effects of the compound by comparing outcomes
in these two cell lines. For instance, A-928605 produced
significant changes both by inhibiting early activation of
molecules within the IGF signaling pathway and transla-
tionally that can be directly attributed to inhibition of
IGF1R because none of these effects occurred in the vector
control line. A-928605 appears to have few off-target
activities in both biochemical and biological contexts
when using a kinase panel and microarray analysis of
NIH-3T3 cells as rough determinants, respectively. We
believe that this cellular analysis is a step beyond and cor-
roborates with the traditional kinome profiling data
because it provides an unbiased read-out of the biological
consequences of treatment with a small molecule inhibi-
tor in live cells. For example, genes from the microarray
analysis include Cdkn1a (p21), which when up-regulated
by 1.5-fold in A-928605-treated CD8-IGF1R cells could
serve to halt the cell cycle in G1 phase. This may lead to
the inhibition of proliferation seen upon treatment with
A-928605 both in vitro and in vivo, especially when cou-
pled with the concurrent down-regulation of Cyclin D1
observed at both the transcriptional and protein levels.
It is also interesting to note that activation of the IGF sig-
naling pathway leads to a down-regulation of endogenous
IGF pathway components when comparing the untreated
vector control line to the CD8-IGF1R line in the microar-
ray experiment. We are not aware of a precedent for this
observation and presume this is due to a regulatory feed-
back loop by the cells in an attempt to quell the high lev-
els of IGF pathway activation observed. This data
corroborates well with data currently seen in the clinic for
antibodies directed against IGF1R in which the body
attempts to compensate for a loss in IGF signaling by
increasing levels of circulating IGF1 and Growth Hor-
mone [35] in a potentially related regulatory feedback
loop.
The IGF1R inhibitor A-928605 was also able to signifi-
cantly retard the growth in a model of neuroblastoma.
Neuroblastoma is the most common extracranial solid
tumor in children, comprising between 8 and 10% of all
childhood cancers. Unfortunately, this disease accounts
for 15% of all childhood cancer deaths, indicating the
poor prognosis of many of the patients [36]. Autocrine
IGF signaling has long been recognized as a mitogenic sig-
nal for the proliferation of neuroblastoma as well as other
childhood tumors [30,31]. Therefore, we analyzed the
effects of A-928605 in a surgical model of neuroblastoma
using SK-N-FI cells injected into the renal subcapsule. SK-
N-FI cells are commonly grown as flank model xenografts,
but we believe that the implantation used in this study
more accurately reflects the true biology of neuroblastoma
by placing the tumor near the adrenal glands of the mouse
sympathetic nervous system. This combination of the
implantation and waiting two weeks after surgery before
treatment with the inhibitor provides a much higher hur-
dle to assess drug efficacy. Treatment of this preclinical
tumor model with A-928605 results in significant growth
inhibition suggesting that this compound may be clini-
cally effective at treating childhood tumors like neuroblas-
toma as well as other adult IGF-dependent tumors.
A-928605 is also efficacious in tumor models when used
in combination with clinically approved therapeutics
designed against EGFR. For instance, human pancreatic
xenografts treated with a combination of the EGFR mon-
oclonal antibody cetuximab and A-928605 results in an
additive effect on tumor growth inhibition when com-
pared to either of these agents dosed as monotherapies.
Combination studies were also performed in the human
NSCLC line HCC827. Interestingly, synergy is seen when
the combination of the EGFR small molecule tyrosine
kinase inhibitor erlotinib is used with A-928605. The
A, Efficacy of A-928605 and cetuximab, alone and in combination, in the MiaPaCa-2 pancreatic xenograft flank modelFigure 6 (see previous p ge)
A, Efficacy of A-928605 and cetuximab, alone and in combination, in the MiaPaCa-2 pancreatic xenograft flank 
model. Beginning on day 16 post tumor cell injection, mice were dosed intraperitoneally with A-928605 at 37.5 mg/kg, b.i.d. 
for 20 days. Cetuximab and human IgG Control were dosed intraperitoneally at 30 mg/kg, once daily, 3×/week for a total of 6 
doses. At the end of the dosing schedule, the %T/Cs (combination vs. vehicle and vs. human IgG control) were approximately 
60 (P < 0.00001) and (combination vs. A-928605 + human IgG Control and vs. cetuximab) were approximately 72 (P < 0.05). 
B, Efficacy of A-928605 and erlotinib in combination in the HCC-827 NCSLC xenograft flank model. Beginning on day 20 post 
tumor cell injection, mice were dosed intraperitoneally with A-928605 at 37.5 mg/kg, b.i.d. for 16 days. Erlotinib was dosed 
orally at 3.1 mg/kg, b.i.d. for 16 days. At the end of the dosing schedule, the %T/Cs (combination vs. vehicle) was 17 (P < 
0.00001) and (combination vs. erlotinib) was 27 (P < 0.005). In a separate arm of the study, A-928605 as a monotherapy was 
not consistently statistically different from its vehicle control (data not shown).Page 11 of 14
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regression in these tumors. This is of particular interest
because clinical data suggests that both the EGFR pathway
and the IGF1R pathway are implicated in NSCLC as dis-
cussed below.
There are additional small molecule clinical candidates
directed against IGF1R that are being investigated, but
monoclonal antibodies targeting IGF1R are currently the
most clinically advanced reagents. These IGF1R specific
antibodies show clear inhibition of tumor growth in
numerous pre-clinical tumor models [37-40]. In the
clinic, these IGF1R antibodies have produced compelling
proof-of-principle data that implicate an important role
for IGF signaling in numerous tumor types including, but
not limited to, NSCLC and Ewing's Sarcoma [35]. Based
on these preliminary clinical results and the preponder-
ance of evidence that IGF plays an essential role in cancer,
it is important that development of small molecule inhib-
itors of IGF1R continue and that they are able to have
their clinical efficacy assessed in a patient population in
need of more molecularly targeted therapies such as A-
928605.
Conclusion
In this study, we demonstrated the in vitro and in vivo
activities of A-928605, a novel pyrazolo [3,4-d]pyrimidine
small molecule inhibitor of IGF1R. IGF signaling is
believed to have multiple roles in cancer from oncogene-
sis to metastasis making it compelling for a targeted ther-
apy approach. A-982605 is selective at inhibiting IGF1R
and effective as a single agent or in combination with clin-
ically approved agents targeting EGFR in several cancer
models in vivo. Our results suggest that A-928605 or simi-
lar molecules it could provide useful clinical therapeutics
in the treatment of cancer.
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Additional File 1
Supplementary Figure S1. Transformed morphology of the CD8-
IGF1R cells. A, Phase contrast images of the NIH-3T3 vector control cells 
versus the NIH-3T3 CD8-IGF1R cells. B, Morphological dose response of 
the CD8-IGF1R line to A-928605 treatment. Cells were plated and 
allowed to adhere and proliferate overnight. The next day compound was 
added and imaging was performed two days later. The cellular morphology 
appears to revert back towards a naive 3T3 fibroblast at concentrations 
near or below the IC50 of A-928605. All images were captured with a 20× 
objective.




Supplementary Figure S2. A-928605 inhibits growth of CD8-IGF1R 
cells in soft agar. Cells were plated in soft agar with an overlay contain-
ing DMSO control (left) or a final concentration of 1 μM A-928605 
(right). Cells were allowed to grow in a tissue culture incubator for three 
weeks before imaging. The 3T3 vector control line was not capable of 
anchorage-independent growth in soft agar (data not shown).




Supplementary Table 1. Key Affymetrix probe sets related to cell cycle, 
growth, proliferation and IGF signaling with significant changes (5% 
False Discovery Rate (FDR), fold change > 1.5) in any of the following 
three comparisons: vehicle-treated CD8-IGF1R line relative to the vehicle-
treated NIH-3T3 vector control line, A-928605-treated 3T3 CD8-IGF1R 
relative to vehicle-treated 3T3 CD8-IGF1R, or A-928605 treated NIH-
3T3 vector control line relative to the vehicle-treated NIH-3T3 vector con-
trol line.
Click here for file
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